Major bleeding associated with anticoagulation remains a problem even with recently introduced direct oral anticoagulants (DOACs). Currently, there is only one agent (i.e., andexanet alfa) approved for the reversal of life-threatening or uncontrolled bleeding associated with activated factor X (FXa) inhibitors rivaroxaban and apixaban. Since its structure resembles FXa, it can bind the natural anticoagulant "tissue factor pathway inhibitor" leading to possible hypercoagulability. Moreover, access to this agent is limited in low-recourse settings because of its high cost. In addition, coagulation assays available to assess DOACs-induced bleeding are not specific, diminishing their usefulness in emergency situations. Here, we report the selection, identification, and characterization of DNA aptamers against apixaban. The aptamer selection was achieved via the systematic evolution of ligands by exponential enrichment (SELEX) technique. After twelve rounds of selection, 16 different apixaban-specific aptamer sequences were successfully obtained. The binding affinities of the selected aptamers were evaluated using fluorescence binding assays showing dissociation constants ranging from 66.32- 184.8 nM. Selected aptamers demonstrated similar secondary structures despite variable primary sequences, and all exhibited stem-loop motifs common in in-vitro selected aptamers. Future work will focus on developing a highly efficient electrochemical biosensing platform capable of measuring apixaban concentrations in biological samples as well as the development of novel antidotes for apixaban utilizing selected aptamers.